MedsFacts.com - the Next-Generation Reference for Medication Safety.
MedsFacts is a unique online community for patients, health care providers, and medical researchers.
Our goal is to provide valuable information for the 60% of Americans (and others worldwide) currently taking prescription drugs.
Easy to use online research interface helps you quickly assess the benefits and potential danger of various treatments.
Analysis of the latest Food & Drug Administration data covers over 18 million drug side effect profiles.
Interactive tools to allow you to collaborate with others to learn more about medications.
Make more informed treatment decisions knowing you consulted MedsFacts analytics - medical research studies that scrutinize drug safety reports.
MedsFacts is a free service, as we believe the usefulness of our platform scales as more people interact with our service.

About this MedsFacts analysis covering adverse side effect reports of INSULINA SIMPLES patients who developed MALIGNANT NEOPLASM PROGRESSION.

MedsFacts provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and MedsFacts user submissions. Between January 2004 and October 2012, 4 individuals taking INSULINA SIMPLES reported MALIGNANT NEOPLASM PROGRESSION to the FDA. A total of 16 INSULINA SIMPLES drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between INSULINA SIMPLES and MALIGNANT NEOPLASM PROGRESSION. In doing so, we compare INSULINA SIMPLES with other drugs that cause MALIGNANT NEOPLASM PROGRESSION, to help you evaluate whether or not INSULINA SIMPLES causes MALIGNANT NEOPLASM PROGRESSION. Likewise, this page shows the most highly-reported side effects of INSULINA SIMPLES, so you can see if MALIGNANT NEOPLASM PROGRESSION ranks among INSULINA SIMPLES's most well-known side effects.
Summary Statistics
Reports of INSULINA SIMPLES causing MALIGNANT NEOPLASM PROGRESSION: 4
Reports of any side effect of INSULINA SIMPLES : 16
Percentage of INSULINA SIMPLES patients where MALIGNANT NEOPLASM PROGRESSION is a reported side effect: 25.0000%

FDA reports of any drug causing MALIGNANT NEOPLASM PROGRESSION : 13496
Average percentage for all medicated patients where MALIGNANT NEOPLASM PROGRESSION is reported as a complication: 0.0846%

Physician opinion on INSULINA SIMPLES as adverse event culprit:

Overall opinion for all reports of this drug:
Most frequent diagnoses/indications for prescribing INSULINA SIMPLES:
DIABETES MELLITUS ( 4 patients )
( 0 patients )
Drugs with high FDA adverse event association with MALIGNANT NEOPLASM PROGRESSION:

ZOMETA (1675 patients)
GLEEVEC (1051 patients)
GEMZAR (884 patients)
DEXAMETHASONE (774 patients)
AREDIA (753 patients)
CISPLATIN (740 patients)
THALOMID (730 patients)
DECADRON (725 patients)
OXYCONTIN (714 patients)
CAPECITABINE (689 patients)
REVLIMID (686 patients)
CARBOPLATIN (646 patients)
XELODA (630 patients)
ASPIRIN (541 patients)
AVASTIN (516 patients)
FLUOROURACIL (514 patients)
LASIX (511 patients)
TAXOL (463 patients)
VELCADE (449 patients)
CYCLOPHOSPHAMIDE (448 patients)
AFINITOR (439 patients)
TAXOTERE (435 patients)
EXJADE (430 patients)
SANDOSTATIN LAR (423 patients)
MORPHINE (418 patients)
ZOFRAN (385 patients)
COUMADIN (382 patients)
PREDNISONE (374 patients)
ALIMTA (362 patients)
DURAGESIC-100 (361 patients)
NEXIUM (354 patients)
OMEPRAZOLE (344 patients)
FOLIC ACID (331 patients)
OXYCODONE HCL (330 patients)
ATIVAN (326 patients)
FENTANYL (321 patients)
PACLITAXEL (316 patients)
FEMARA (305 patients)
HERCEPTIN (291 patients)
GEMCITABINE (291 patients)
VICODIN (287 patients)
ETOPOSIDE (284 patients)
FUROSEMIDE (279 patients)
DURAGESIC (273 patients)
MEGACE (270 patients)
ACETAMINOPHEN (267 patients)
DEXAMETHASONE TAB (266 patients)
THALIDOMIDE (265 patients)
MORPHINE SULFATE (264 patients)
PREDNISOLONE (260 patients)
MS CONTIN (257 patients)
PROTONIX (256 patients)
ALLOPURINOL (253 patients)
AMBIEN (253 patients)
COMPAZINE (252 patients)
BEVACIZUMAB (251 patients)
LORAZEPAM (249 patients)
CETUXIMAB (245 patients)
PERCOCET (245 patients)
METHOTREXATE (239 patients)
LIPITOR (237 patients)
OXALIPLATIN (236 patients)
IRESSA (231 patients)
VITAMIN B-12 (231 patients)
ATENOLOL (225 patients)
RADIATION THERAPY (224 patients)
PRILOSEC (223 patients)
TARCEVA (217 patients)
LISINOPRIL (217 patients)
NEURONTIN (217 patients)
ARIMIDEX (216 patients)
IRINOTECAN HCL (216 patients)
SYNTHROID (213 patients)
ARANESP (211 patients)
NAVELBINE (208 patients)
POTASSIUM CHLORIDE (206 patients)
FAMOTIDINE (200 patients)
NORVASC (200 patients)
METOCLOPRAMIDE (198 patients)
PROCRIT (194 patients)
LEVAQUIN (192 patients)
DOCETAXEL (189 patients)
ALBUTEROL (188 patients)
PAXIL (186 patients)
TAMOXIFEN CITRATE (185 patients)
CHEMOTHERAPEUTICS NOS (185 patients)
MAGNESIUM OXIDE (182 patients)
ACYCLOVIR (181 patients)
VINCRISTINE (176 patients)
CYTOXAN (174 patients)
LEUCOVORIN CALCIUM (173 patients)
LOVENOX (173 patients)
ERLOTINIB HYDROCHLORIDE (173 patients)
FASLODEX (172 patients)
NEXAVAR (171 patients)
HYDROCHLOROTHIAZIDE (171 patients)
ADRIAMYCIN PFS (170 patients)
FLUCONAZOLE (169 patients)
DOXORUBICIN HCL (168 patients)
SORAFENIB (168 patients)
ZANTAC (167 patients)
ONDANSETRON (167 patients)
LANSOPRAZOLE (167 patients)
LOXONIN (165 patients)
DUROTEP (165 patients)
CELEBREX (164 patients)
CYTARABINE (164 patients)
WARFARIN SODIUM (163 patients)
CALCIUM (155 patients)
ERBITUX (155 patients)
SUTENT (154 patients)
LEVOTHYROXINE SODIUM (153 patients)
XANAX (153 patients)
ZOLOFT (153 patients)
DILAUDID (152 patients)
DOXIL (152 patients)
PREDNISONE TAB (149 patients)
OXYCODONE (147 patients)
DIFLUCAN (146 patients)
LEXAPRO (144 patients)
VITAMIN D (143 patients)
BENADRYL (143 patients)
KYTRIL (142 patients)
ZOCOR (142 patients)
GABAPENTIN (141 patients)
PREVACID (141 patients)
TEMOZOLOMIDE (140 patients)
IBUPROFEN (139 patients)
SENOKOT (139 patients)
PARAPLATIN (137 patients)
SIMVASTATIN (135 patients)
AROMASIN (134 patients)
ERLOTINIB (ERLOTINIB) (TABLET) (ERLOTINIB) (132 patients)
NEUPOGEN (131 patients)
COLACE (129 patients)
TASIGNA (128 patients)
LACTULOSE (125 patients)
REGLAN (122 patients)
ELOXATIN (122 patients)
PROCHLORPERAZINE (120 patients)
AMLODIPINE (118 patients)
CYCLOSPORINE (118 patients)
CASODEX (117 patients)
TEMODAL (116 patients)
DIOVAN (115 patients)
DIGOXIN (114 patients)
LYRICA (114 patients)
MELPHALAN (114 patients)
GEMCITABINE HCL (113 patients)
INSULIN (113 patients)
NEULASTA (113 patients)
ALDACTONE (111 patients)
BACTRIM (108 patients)
MULTI-VITAMINS (108 patients)
RANITIDINE (108 patients)
AMOXICILLIN (108 patients)
PEPCID (108 patients)
ZOLADEX (108 patients)
MYLOTARG (107 patients)
METOPROLOL TARTRATE (105 patients)
CIPROFLOXACIN (104 patients)
SPRYCEL (102 patients)
ZOLEDRONIC ACID (102 patients)
DASATINIB (102 patients)
PAMIDRONATE DISODIUM (102 patients)
ALOXI (100 patients)
LORTAB (99 patients)
CELEXA (99 patients)
SUNITINIB MALATE (99 patients)
DICLOFENAC SODIUM (99 patients)
LEVOFLOXACIN (98 patients)
TOPROL-XL (98 patients)
PREDONINE (98 patients)
RADIOTHERAPY (98 patients)
PLAVIX (97 patients)
PEMETREXED (97 patients)
TAKEPRON (97 patients)
MIRALAX (97 patients)
HEPARIN (96 patients)
MORPHINE HYDROCHLORIDE (96 patients)
FOSAMAX (95 patients)
METFORMIN HCL (95 patients)
SENNA (94 patients)
ICL670A ICL+DISTAB (91 patients)
VANCOMYCIN (91 patients)
FLUDARABINE PHOSPHATE (90 patients)
VIOXX (90 patients)
TRASTUZUMAB (88 patients)
KEPPRA (88 patients)
GASTER (88 patients)
CYMBALTA (87 patients)
TEMODAR (87 patients)
VOLTAREN (87 patients)
HYDROCODONE (86 patients)
TRAMADOL HCL (86 patients)
TYLENOL (84 patients)
RITUXIMAB (84 patients)
EPOGEN (84 patients)
NOVAMIN (83 patients)
MAGNESIUM OXIDE (MAGNESIUM OXIDE) (83 patients)
MULTI-VITAMIN (83 patients)
RADIATION (81 patients)
RED BLOOD CELLS (81 patients)
STI571/CGP57148B T35717+CAPS (81 patients)
ALLEGRA (81 patients)
SOLU-MEDROL (80 patients)
PANTOPRAZOLE SODIUM (79 patients)
IMODIUM (79 patients)
NYSTATIN (79 patients)
LOXONIN (LOXOPROFEN SODIUM) (79 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the MedsFacts community - currently one million members and growing! MedsFacts online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.


Recent MedsFacts Activity for INSULINA SIMPLES


Issue Description / Topic Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited MedsFacts. If you have a question about MALIGNANT NEOPLASM PROGRESSION and INSULINA SIMPLES, post it here. You may receive a response from a fellow patient - or a leading expert in the field.
Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited MedsFacts. If you have a noteworthy experience as a patient taking INSULINA SIMPLES, post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.
Your Experience or Concern:

Telemedicine Expert Consults MedsFacts newest feature allows patients to consult - via realtime videoconferencing - experts in INSULINA SIMPLES. This premium feature connects patients to experts, regardless of geography. MedsFacts experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.
We are currently accepting registration for INSULINA SIMPLES experts. If you are a healthcare provider experienced in prescribing INSULINA SIMPLES, please register here.
© 2014 MedsFacts, Inc
Privacy Policy
Terms of Use